Company Overview
AtriCure, Inc. engages in the development, manufacture, and sale of specialized devices designed for surgical ablation of cardiac tissue, the exclusion of the left atrial appendage, and the temporary blocking of pain via the ablation of peripheral nerves. The company operates within the healthcare sector, specifically serving the medical instruments and supplies industry, which positions it as a critical supplier of surgical technology to medical centers globally. This business model serves a broad geographic footprint that includes the United States, the Asia-Pacific region, and international markets. The company currently holds a market capitalization of $1.47 billion and reports annual revenue of $534.53 million, employing a workforce of 1,350 individuals. These financial figures indicate that AtriCure holds a substantial position within the medical device market, supporting a significant operational scale that allows for extensive R&D and global distribution capabilities.
Financial Health
The company reported revenue of $534.53 million for the trailing twelve months, while recording a net income of -$11,448,000 and an EBITDA of $11.08 million. The significant gap between the positive revenue and the negative net income reveals a substantial cost structure burden, where operating expenses and taxes have exceeded gross profit margins to the point of generating a loss on the bottom line. Despite the accounting loss, the company generated free cash flow of $38.94 million, which indicates a strong level of financial flexibility and the ability to fund operations without relying on external capital injections. Profitability analysis shows a gross margin of 75.0%, an operating margin of 1.8%, and a profit margin of -2.1%. The high gross margin suggests efficient manufacturing and pricing power, whereas the low operating margin and negative profit margin indicate that high overhead costs or specific one-time charges are eroding overall profitability. On the balance sheet, the company holds $167.43 million in cash against $76.42 million in debt, resulting in a debt-to-equity ratio of 15.54. Although the debt-to-equity ratio appears elevated numerically, the substantial cash reserve suggests the balance sheet is not leveraged to a dangerous degree, as cash significantly outweighs debt obligations. The current ratio stands at 3.96, which indicates a very strong position regarding short-term liquidity and the ability to cover immediate obligations. Return on equity is -2.4% and return on assets is -0.9%, metrics that reveal that management is currently not generating returns on shareholder capital or assets, reflecting the impact of the net loss on overall efficiency.
Valuation Assessment
The valuation metrics present a complex picture with a trailing P/E ratio of N/A and a forward P/E of 88.32. The absence of a trailing P/E due to negative earnings, contrasted with a high forward P/E, implies that the market is pricing in significant future earnings improvements that are not yet reflected in current financial statements. The price-to-book ratio is 3.00, indicating that the stock trades at a premium of three times its book value, which suggests investors are willing to pay significantly more than the net asset value of the company. Alternative valuation metrics include a price-to-sales ratio of 2.76 and an EV/EBITDA of 124.85, which suggest the market is valuing the company primarily on its revenue generation and cash flow potential rather than current profitability. The stock has a 52-week high of $43.18 and a 52-week low of $28.29. Without a specific current price provided in the available facts, the valuation range establishes a trading band within which the stock has performed over the past year, with the forward P/E suggesting expectations of price appreciation if earnings normalize. The beta is 1.44, which means the stock exhibits higher price volatility relative to the broader market, moving 44% more than the market average in response to general market fluctuations.
Growth & Income
Revenue growth for the trailing twelve months is 13.1%, while earnings growth is N/A due to the negative net income. The divergence between positive revenue growth and the inability to calculate earnings growth implies that top-line expansion is outpacing the bottom-line performance, suggesting the company is reinvesting heavily or facing margin compression before achieving profitability. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders but instead reinvests all earnings back into the business to fuel growth and reduce debt. This strategy of retaining earnings rather than paying dividends is typical for companies in a growth phase that prioritize capital allocation toward research and development or operational scaling. The overall growth and income profile is characterized by strong top-line expansion supported by robust free cash flow, though the lack of current earnings and dividends reflects a transitional period in the company's financial lifecycle.